Printer Friendly

ANOTHER CORDIS ANGIOPLASTY CATHETER APPROVED FOR US MARKET RELEASE

 MIAMI, July 27 /PRNewswire/ -- Cordis Corporation (NASDAQ-NMS: CORD) said today that the Food and Drug Administration (FDA) has approved the U.S. market release of another line of angioplasty catheters, the Predator dilatation catheter -- the company's sixth such approval in the past four weeks. Dilatation, or balloon, catheters are used to open coronary arteries occluded by the buildup of fatty deposits, or plaque, asociated with atherosclerosis.
 Robert C. Strauss, president and chief executive officer, called the action an "affirmation of our increasingly productive research and regulatory efforts associated with angioplasty catheter technologies. Predator represents another excellent product line, but the significance of today's announcement is best understood when viewed within the context of the past few weeks. Cordis," he continued, "has been presented a unique opportunity. We intend to make the most of it."
 The world's leading supplier of catheters for diagnosing coronary artery disease, Cordis has been gaining momentum in the higher-margin, faster-growing angioplasty market in recent months, helped in part by the sale of the newer lines of catheters, some of which have been marketed outside the US for up to nine months. The Predator approval represents the company's ninth balloon dilatation device to gain FDA release since July 1992.
 The Predator, like the company's recently approved Sleek catheter line, is designed to compete in the largest segment of the U.S. angioplasty market -- catheters compatible with up to 014" guidewires. Featuring a unique tip and shaft design, Predator offers enhanced pushability and trackability, thus enabling physicians to more easily guide the balloon to and across occluded, distal coronary lesions.
 Like all Cordis dilatation devices, Predator catheters feature a proprietary Duralyn balloon. Low-profile and optimally compliant, Duralyn provides maximum flexibility in delivering increased force while keeping the balloon's diameter below the ceiling of safety. Similarly, the material's acknowledged strength enables doctors to inflate the balloon to higher than normal pressures in the hope of "cracking" or displacing severely calcified lesions.
 Shipments of Predator catheters are expected to begin in the fall. Cordis, with balloon manufacturing capacity in both its Miami and Roden, The Netherlands, facilities, is in the process of scaling-up production to meet the increasing demand for its many recently approved balloon catheters.
 Miami-based Cordis Corporation manufactures and markets a variety of medical devices and systems for the angiographic and neuroscience markets.
 -0- 7/27/93
 /CONTACT: Chick McDowell, vice president, corporate relations and assistant secretary of Cordis Corporation, 305-824-2821/
 (CORD)


CO: Cordis Corporation ST: Florida IN: MTC SU:

RC-JB -- FL001 -- 6046 07/27/93 08:28 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 27, 1993
Words:421
Previous Article:SORICON ANNOUNCES $1 MILLION IN PURCHASE ORDERS FROM KING SOOPERS AND LARGE NATIONAL CHECK VERIFICATION COMPANY
Next Article:SYNTELLECT DELIVERS FIRST PC-BASED VOICE PROCESSING SYSTEMS
Topics:


Related Articles
CORDIS' SLEUTH ANGIOPLASTY CATHETER GAINS MARKET APPROVAL
CORDIS' ORION SOFT TIP ANGIOPLASTY CATHETER GAINS MARKET APPROVAL
TWO NEW CORDIS ANGIOPLASTY CATHETERS GAIN U.S. MARKET RELEASE
CORDIS' SLEEK CATHETER RECEIVES "APPROVABLE LETTER"
FOUR CORDIS ANGIOPLASTY CATHETERS APPROVED FOR US MARKET RELEASE
CORDIS PREDATOR LONG BALLOON CATHETERS APPROVED FOR U.S. MARKET RELEASE
CORDIS TRAKSTAR ANGIOPLASTY CATHETERS APPROVED FOR US MARKET RELEASE
CORDIS GAINS FDA APPROVAL FOR FOUR NEW ANGIOPLASTY CATHETERS
CORDIS MAGNETIC RAPID-EXCHANGE SYSTEM GAINS FDA APPROVAL
Medtronic Releases Multi-Purpose Millenia Catheter to U.S. Angioplasty Market

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters